Intermediate-term outcomes of hepatitis C-positive compared with hepatitis C-negative deceased-donor renal allograft recipients.
BACKGROUND
Prior studies have yielded conflicting results concerning the impact of HCV on renal transplant outcomes.


METHODS
We examined outcomes in comparable groups of predominantly African American hepatitis C virus (HCV)-positive (n = 34) and HCV-negative (n = 111) kidney transplant patients receiving contemporary immunosuppression.


RESULTS
There was no difference in patient survival or acute rejection, but new-onset diabetes (NODM) was increased and graft survival decreased in the HCV-positive group, with increased graft loss secondary to noncompliance and Type I MPGN. The incidence of NODM among patients undergoing early corticosteroid withdrawal was 11% in both groups, while among those on prednisone, it was 47% in HCV-positive versus 25% in HCV-negative recipients.


CONCLUSIONS
Deceased-donor HCV-positive renal allograft recipients have equivalent patient but decreased graft survival. Noncompliance and Type I MPGN play a role in producing this negative effect on graft outcome. Steroids may be required for HCV to exert its diabetogenicity in kidney transplant patients.
Brown
Kristian L
KL
Section of Transplant Surgery, Department of Surgery, Wayne State University School of Medicine, Detroit, MI 48201, USA.
El-Amm
Jose M
JM
Doshi
Mona D
MD
Singh
Atul
A
Morawski
Katherina
K
Cincotta
Elizabeth
E
Siddiqui
Firdous
F
Losanoff
Julian E
JE
West
Miguel S
MS
Gruber
Scott A
SA
D003920:Diabetes Mellitus; D005260:Female; D006085:Graft Survival; D006526:Hepatitis C; D006801:Humans; D016030:Kidney Transplantation / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D014019:Tissue Donors; D014184:Transplantation, Homologous; D016896:Treatment Outcome